Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financial Disclosure Policy For Commenters Detailed In FDA Draft Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

The document, intended for industry reps, consumer associations and other stakeholders, explains how to secure a time slot for public portions of FDA meetings and “encourages” disclosure of financial relationships. The draft guidance is released shortly before the advisory committee on the safety of COX-2 inhibitors.

You may also be interested in...



ICMJE Clinical Trial Registration Criteria Could Exempt High-Risk Medical Devices, Says IoM Report

The Institute’s Board on Health Sciences Policy is preparing a clinical trials registry for fall release.

IoM Pediatric Report Calls For Congressional Action, Better Collaboration

Institute says independent safety board may not be appropriate for devices, but experiences learned from the drug safety board may apply.

Combo Products Collaboration Up To Industry, Not FDA – RAPS Summit

Although drug companies can be reluctant to partner with device firms on combo products, it is not FDA’s role to coerce firms to partner on cross-labeling development, participants at a Regulatory Affairs Professionals Society summit say. FDA will hold a meeting on cross-labeling in the spring.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel